INOGRAFT BIOTHERAPEUTICS Trademark

Trademark Overview


On Monday, May 13, 2024, a trademark application was filed for INOGRAFT BIOTHERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the INOGRAFT BIOTHERAPEUTICS trademark a serial number of 98547760. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, February 18, 2025. This trademark is owned by Inograft Biotherapeutics, Inc.. The INOGRAFT BIOTHERAPEUTICS trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Stem cell-derived drug therapies being biological preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cell-derived therapeutic pharmaceutical preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cells for therapeutic treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases for medical purposes; pharmaceutical preparations as CD47 antagonists, integrin-associated proteins (IAP), and CD47 glycoproteins for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; monoclonal antibodies for medical purposes; monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants for medical purposes

Stem cells for research purposes; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; decoy receptors being biochemicals for in vitro scientific or research use

Research and development services relating to bone marrow, stem cell, and organ transplantation; research and development in the field of stem cell therapies; research and development relating to bone marrow, stem-cell, and organ transplantation; research and development relating to pharmaceutical preparations as CD47 antagonists, integrin-associated proteins, and CD47 glycoproteins; research and development services in the field of antibodies; research and development relating to using monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants
inograft biotherapeutics

General Information


Serial Number98547760
Word MarkINOGRAFT BIOTHERAPEUTICS
Filing DateMonday, May 13, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, February 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2024

Trademark Statements


Goods and ServicesStem cell-derived drug therapies being biological preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cell-derived therapeutic pharmaceutical preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cells for therapeutic treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases for medical purposes; pharmaceutical preparations as CD47 antagonists, integrin-associated proteins (IAP), and CD47 glycoproteins for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; monoclonal antibodies for medical purposes; monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants for medical purposes
Goods and ServicesStem cells for research purposes; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; decoy receptors being biochemicals for in vitro scientific or research use
NOT AVAILABLE"BIOTHERAPEUTICS"
Goods and ServicesResearch and development services relating to bone marrow, stem cell, and organ transplantation; research and development in the field of stem cell therapies; research and development relating to bone marrow, stem-cell, and organ transplantation; research and development relating to pharmaceutical preparations as CD47 antagonists, integrin-associated proteins, and CD47 glycoproteins; research and development services in the field of antibodies; research and development relating to using monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateMonday, May 13, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, May 13, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, May 13, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameInograft Biotherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPalo Alto, CA 94304

Party NameInograft Biotherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPalo Alto, CA 94304

Trademark Events


Event DateEvent Description
Monday, May 13, 2024NEW APPLICATION ENTERED
Wednesday, November 13, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 3, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, November 26, 2024ASSIGNED TO EXAMINER
Tuesday, December 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 3, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 3, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 3, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, December 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 18, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT